Table 1.
Clinical and metabolic characteristics before and after treatment with muraglitazar (5 mg/day) or placebo for 16 weeks
| Placebo | Muraglitazar | P† | |||||
|---|---|---|---|---|---|---|---|
| Pre | Post | Change (%) | Pre | Post | Change (%) | ||
| Number | 4 | 12 | |||||
| Sex | 2F/2M | 8F/4M | |||||
| Age (years) | 54 ± 6 | 50 ± 3 | |||||
| BMI (kg/m2) | 30.1 ± 2.4 | 29.1 ± 2.3 | −3.3 | 33.3 ± 0.8 | 34.3 ± 0.8* | +3 | 0.024 |
| Fasting plasma glucose (mmol/1) | 11.1 ± 1.4 | 9.8 ± 1.9 | −11.7 | 10.5 ± 0.7 | 7.3 ± 0.4* | −30.5 | 0.010 |
| Fasting plasma insulin (pmol/1) | 77.4 ± 45 | 57.0 ± 22.2 | −26.4 | 87.0 ± 21.6 | 48.6 ± 9.0* | −44.1 | NS |
| HbA1c (mmol/mol) | 67 | 61 | 72 | 52 | |||
| HbAlc (%) | 8.3 ± 0.8 | 7.7 ± 1.1 | −7.2 | 8.7 ± 0.6 | 6.9 ± 0.5* | −20.7 | NS |
| Total glucose disposal (μmo1/kg/min) | 14 ± 4 | 15 ± 2 | +7.1 | 16 ± 2 | 29 ± 3* | +81.3 | 0.0023 |
| Triglycerides (mmol/1) | 1.80 ± 0.32 | 1.91 ± 0.15 | +6.1 | 1.74 ± 0.16 | 1.06 ± 0.10* | −39.1 | < 0.0001 |
| Total cholesterol (mmol/1) | 4.82 ± 0.44 | 4.25 ± 0.60 | −11.8 | 4.40 ± 0.16 | 4.12 ± 0.16* | −6.4 | NS |
| HDL cholesterol (mmol/1) | 1.35 ± 0.21 | 1.09 ± 0.21 | −19.3 | 1.01 ± 0.08 | 1.14 ± 0.08* | +12.9 | NS |
| LDL cholesterol (mmol/1) | 3.00 ± 0.41 | 2.64 ± 0.57 | −12.0 | 2.56 ± 0.18 | 2.31 ± 0.21 | −9.8 | NS |
Data represent mean ± SE.
*
P < 0.05 versus pre-treatment.
†
P-value (ANOVA) for the comparison between muraglitazar and placebo therapy-treated groups (change from baseline).